About Us

BioCheetah Pte Ltd is a Singapore-based, A*STAR-IMCB spin-off diagnostics company. It is primarily set up to develop and commercialize non-invasive, protein-based immunodiagnostic applications. First diagnostic applications in development are based on the proprietary bladder cancer biomarkers and detection antibodies discovered and developed in IMCB. Both Intellectual Property of bladder cancer biomarkers and detection antibodies are exclusively licensed from A*STAR. Products to be developed include professional use in-vitro diagnostic VECanDx ELISA and Point-Of-Care Test (POCT) kits. The kits will employ a novel multiplex urine-based biomarkers panel with high sensitivity and specificity for diagnosis and monitoring of bladder cancer. BioCheetah’s target markets are to encompass local and overseas public and private healthcare providers. In addition, clinical trials for clinical validation of the bladder cancer diagnostic products is currently underway with Singapore General Hospital and several hospitals in China.

BioCheetah is ISO 13485:2016 certified for design and development Medical device of its R&D facilities located in Singapore.

Our Certifications

• ISO 13485:2016

Our Vision

Leader in urinalysis for urological cancers.

Our Mission

Delivering innovative healthcare diagnostics for better detection and management of urological cancers.

Our Promise

Our early cancer detection technology delivers pain-free biopsy and better patient triage assessment.